

INTRODUCTION	XXVII
STUDY GOALS AND OBJECTIVES.....	XXVII
REASONS FOR DOING THE STUDY	XXVII
SCOPE AND FORMAT	XXVII
METHODOLOGY	XXVIII
ANALYST CREDENTIALS.....	XXVIII
RELATED BCC STUDIES	XXVIII
SUMMARY.....	XXX
SUMMARY TABLE TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, THROUGH 2007 (\$ BILLIONS, %).....	XXX
SUMMARY FIGURE TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, 2000- 2007 (\$ BILLIONS).....	XXXI
INDUSTRY OVERVIEW.....	1
THEORIES OF AGING	1
BIOLOGICAL THEORIES	1
CAUSAL THEORIES.....	1
PSYCHOLOGICAL THEORIES.....	2
AGING IN VARIOUS CULTURES.....	2
AGE-RELATED CHANGES IN THE ELDERLY	3
CARDIOVASCULAR SYSTEM.....	3
Cardiovascular System (Continued).....	4
ENDOCRINE SYSTEM	5
FEMALE REPRODUCTIVE SYSTEM	5
GASTROINTESTINAL SYSTEM AND NUTRITION.....	6
Gastrointestinal System and Nutrition (Continued)	7
INTEGUMENTARY SYSTEM	8
MUSCULOSKELETAL SYSTEM	9
NEUROLOGICAL SYSTEM.....	10
PULMONARY SYSTEM.....	11
RENAL AND URINARY SYSTEM.....	11
DISEASES AND CONDITIONS AFFECTING THE ELDERLY	
POPULATION	13
TABLE 1 MOST COMMON ILLNESSES IN THE OLDER AGE GROUP.....	13
HISTORY AND GROWTH OF THE ELDERLY DRUG MARKET	14
TABLE 2 PRESCRIPTION DRUG USE BY AGE GROUP	14
TABLE 3 AVERAGE ANNUAL PRESCRIPTION DRUG EXPENDITURES, BY AGE GROUP (\$).....	15
DRUG THERAPY IN THE ELDERLY	15
PHARMACOKINETIC CHANGES	15
Absorption.....	15
Distribution.....	16
Metabolism.....	17
Excretion	17

RATIONAL DRUG THERAPY	18
POLYPHARMACY	19
ADVERSE DRUG REACTIONS.....	20
<i>TABLE 4 COMMONLY OBSERVED ADVERSE DRUG REACTIONS IN THE</i>	
<i>ELDERLY.....</i>	<i>20</i>
NONCOMPLIANCE	21
MEDICATION MANAGEMENT.....	22
DEMOGRAPHICS, INCIDENCE, MORTALITY	22
AGING IN AMERICA	22
<i>TABLE 5 U.S. POPULATION ESTIMATES AND PROJECTIONS, BY AGE GROUP,</i>	
<i>FOR SPECIFIC YEARS, 1900 TO 2050 (THOUSANDS).....</i>	<i>23</i>
<i>FIGURE 1 U.S. POPULATION ESTIMATES AND PROJECTIONS, BY AGE GROUP,</i>	
<i>FOR SPECIFIC YEARS, 1900-2050.....</i>	<i>23</i>
<i>TABLE 6 ESTIMATED U.S. POPULATION, BY AGE GROUP, THROUGH 2007</i>	
<i>(THOUSANDS).....</i>	<i>24</i>
GENDER AND AGE	24
<i>TABLE 7 ESTIAMTES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH AND</i>	
<i>PROJECTIONS, BY SEX, 2000, 2005 AND 2010 (YEARS).....</i>	<i>25</i>
U.S. GEOGRAPHIC DISTRIBUTION	25
<i>TABLE 8 ESTIMATED U.S. ELDERLY (AGE 65 AND UP) POPULATION, BY U.S.</i>	
<i>STATE, 2000 AND 2025 (THOUSANDS).....</i>	<i>26</i>
<i>TABLE 8 (CONTINUED)</i>	<i>27</i>
MARITAL STATUS.....	27
<i>TABLE 9 MARITAL STATUS OF THE 65 AND OVER AGE POPULATION BY SEX,</i>	
<i>2001 (THOUSANDS).....</i>	<i>27</i>
ECONOMIC STATUS.....	28
<i>TABLE 10 HOUSEHOLD INCOME BY SELECTED AGE GROUP, 2001 (\$</i>	
<i>THOUSANDS).....</i>	<i>28</i>
<i>TABLE 11 POVERTY LEVEL OF PERSONS 65 YEARS AND OVER BY SELECTED</i>	
<i>CHARACTERISTIC, 1999 (THOUSANDS, %)</i>	<i>29</i>
HEALTH CARE	29
<i>TABLE 12 DEATHS OF 65 AND OVER POPULATION, BY RACE AND LEADING</i>	
<i>CAUSE, 1998</i>	<i>30</i>
<i>TABLE 13 PERCENT DISTRIBUTION OF NUMBER OF VISITS TO HEALTH CARE</i>	
<i>PROFESSIONALS BY SELECTED AGE GROUP, 1998.....</i>	<i>30</i>
<i>TABLE 14 HOSPITAL DISCHARGES AND DAYS OF CARE BY ELDERLY AGE</i>	
<i>GROUP, 1999 (# THOUSANDS).....</i>	<i>31</i>
LONG-TERM CARE	31
<i>TABLE 15 POPULATION 65 YEARS AND OVER BY AGE FOR NURSING HOMES,</i>	
<i>HOME HEALTH, OR HOSPICE CARE, ESTIMATED 2000</i>	<i>32</i>
TRENDS AFFECTING THE MARKET.....	32
PUBLIC POLICY DEVELOPMENT.....	32
INSURANCE ISSUES, MEDICARE, MANAGED CARE,	
HEALTH CARE FUNDING	33
Social, Legal, and Ethical Issues	33
<i>TABLE 16 SELECTED RACIAL ORIGINS OF 65 YEAR AND OVER U.S.</i>	
<i>POPULATION, 2000 (THOUSANDS, %)</i>	<i>34</i>
MASS MEDIA ATTITUDE	34
POLITICAL INVOLVEMENT.....	35

GENERIC DRUGS.....	35
Generic Drugs (Continued).....	36
THE AGING NETWORK.....	37
The Aging Network (Continued).....	38
MARKET ANALYSIS.....	39
ANTI-INFECTIVE AGENTS	39
OVERVIEW	39
PRODUCT DESCRIPTION	39
Product Description (Continued)	40
Product Description (Continued)	41
TABLE 17 SELECTED U.S. ANTI-INFECTIVE AGENT COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY.....	42
TABLE 17 (CONTINUED)	43
TABLE 17 (CONTINUED)	44
RESEARCH AND DEVELOPMENT	45
TABLE 18 U.S. ELDERLY ANTI-INFECTIVE AGENTS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE	45
MARKET SIZE AND GROWTH.....	45
Total Market	45
TABLE 19 TOTAL U.S. ANTI-INFECTIVE AGENT MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	46
FIGURE 2 TOTAL U.S. ANTI-INFECTIVE AGENT MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS, %)	46
TABLE 20 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET BY PRODUCT SUB- TYPE, THROUGH 2007 (\$ MILLIONS).....	47
FIGURE 3 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET BY PRODUCT SUB- TYPE, 2000-2007 (\$ MILLIONS).....	48
Market Percent Distribution by Product Sub-type	48
TABLE 21 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, THROUGH 2007 (%).....	49
FIGURE 4 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)	50
COMPETITIVE STRUCTURE AND MARKET SHARE.....	50
Competitive Structure And Market Share (Continued)	51
TABLE 22 U.S. ELDERLY ANTI-INFECTIVE AGENTS MARKET, COMPETITIVE MARKET SHARE, 2002 (\$ MILLIONS).....	52
FIGURE 5 U.S. ELDERLY ANTI-INFECTIVE AGENTS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002	53
CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS.....	53
OVERVIEW	53
TABLE 23 COMMON CAUSES OF CONGESTIVE HEART FAILURE.....	54
Incidence and Prevalence	54
Advances in Prevention and Treatment.....	55
Advances in Prevention and Treatment (Continued).....	56
Hypercholesterolemia.....	57
Hypertension.....	58

PRODUCT DESCRIPTION	59
Product Description (Continued)	60
TABLE 24 <i>SELECTED U.S. CARDIOVASCULAR DRUG AND BLOOD MODIFIERS</i> <i>COMPARISON, DRUGS COMMONLY USED BY THE ELDELRY</i>	61
TABLE 24 (CONTINUED)	62
TABLE 24 (CONTINUED)	63
RESEARCH AND DEVELOPMENT	63
TABLE 25 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE</i>	63
TABLE 25 (CONTINUED)	64
MARKET SIZE AND GROWTH.....	64
Total Market	64
TABLE 26 <i>TOTAL U.S. CARDIOVASCULAR DRUG AND BLOOD MODIFIER</i> <i>MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE</i> <i>65, THROUGH 2007 (\$ BILLIONS)</i>	65
FIGURE 6 <i>TOTAL U.S. CARDIOVASCULAR DRUG AND BLOOD MODIFIER</i> <i>MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE</i> <i>65, 2002 AND 2007 (\$ BILLIONS, %)</i>	65
Total Market (Continued).....	66
TABLE 27 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS)</i>	67
FIGURE 7 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS)</i>	67
Market Percent Distribution by Product Sub-type	68
TABLE 28 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)</i>	69
FIGURE 8 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)</i>	69
COMPETITIVE STRUCTURE AND MARKET SHARE.....	70
TABLE 29 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>MARKET, COMPETITIVE MARKET SHARE, 2002 (\$ MILLIONS)</i>	71
FIGURE 9 <i>U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS</i> <i>MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)</i>	72
CENTRAL NERVOUS SYSTEM DRUGS	72
OVERVIEW	72
Alzheimer's Disease.....	73
Anxiety	74
Cerebrovascular Disease	75
Dementia.....	76
Depression.....	77
TABLE 30 <i>DRUGS THAT MAY PRECIPITATE DEPRESSION</i>	77
Epilepsy.....	78
Osteoarthritis.....	79
Osteoarthritis (Continued)	80
Osteoarthritis (Continued)	81
Parkinson's Disease.....	82
Rheumatoid Arthritis	82
TABLE 31 <i>SELECTED U.S. CENTRAL NERVOUS SYSTEM DRUG COMPARISON,</i> <i>DRUGS COMMONLY USED BY THE ELDERLY</i>	83

TABLE 31 (CONTINUED)	84
TABLE 31 (CONTINUED)	85
TABLE 31 (CONTINUED)	86
RESEARCH AND DEVELOPMENT	86
TABLE 32 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE	87
TABLE 32 (CONTINUED)	88
MARKET SIZE AND GROWTH	89
Total Market	89
TABLE 33 TOTAL U.S. CENTRAL NERVOUS SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	89
FIGURE 10 TOTAL U.S. CENTRAL NERVOUS SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS, %).....	90
TABLE 34 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS).....	91
FIGURE 11 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS).....	92
Market Percent Distribution by Product Sub-type	92
TABLE 35 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, THROUGH 2007 (%).....	93
FIGURE 12 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%).....	94
COMPETITIVE STRUCTURE AND MARKET SHARE.....	94
Competitive Structure and Market Share (Continued)	95
TABLE 36 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	96
FIGURE 13 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%).....	97
DERMATOLOGIC AND SENSORY ORGAN DRUGS	97
OVERVIEW	97
PRODUCT DESCRIPTION	98
Product Description (Continued)	99
TABLE 37 SELECTED U.S. DERMATOLOGIC AND SENSORY ORGAN DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY.....	100
TABLE 37 (CONTINUED)	101
TABLE 37 (CONTINUED)	102
RESEARCH AND DEVELOPMENT	102
TABLE 38 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE	102
TABLE 38 (CONTINUED)	103
MARKET SIZE AND GROWTH	103
Total Market	103
TABLE 39 TOTAL U.S. DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	103
FIGURE 14 TOTAL U.S. DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS, %).....	104

TABLE 40 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS)	105
FIGURE 15 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS).....	105
Market Percent Distribution by Product Sub-type	105
TABLE 41 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)	106
FIGURE 16 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)	106
COMPETITIVE STRUCTURE AND MARKET SHARE.....	107
TABLE 42 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	108
FIGURE 17 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002.....	108
GASTROINTESTINAL DRUGS	109
OVERVIEW	109
PRODUCT DESCRIPTION	110
Product Description (Continued)	111
Product Description (Continued)	112
TABLE 43 SELECTED U.S. GASTROINTESTINAL DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY.....	113
RESEARCH AND DEVELOPMENT	113
TABLE 44 U.S. ELDERLY GASTROINTESTINAL DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE.....	114
MARKET SIZE AND GROWTH.....	114
Total Market	114
TABLE 45 TOTAL U.S. GASTROINTESTINAL DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	115
FIGURE 18 TOTAL U.S. GASTROINTESTINAL DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002-2007 (\$ BILLIONS, %).....	115
TABLE 46 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS).....	116
FIGURE 19 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS)	117
Market Percent Distribution by Product Sub-type	117
TABLE 47 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)	118
FIGURE 20 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%).....	118
COMPETITIVE STRUCTURE AND MARKET SHARE.....	119
TABLE 48 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	119
TABLE 48 (CONTINUED)	120
FIGURE 21 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	120
KIDNEY AND URINARY SYSTEM DRUGS	121
OVERVIEW	121
PRODUCT DESCRIPTION	122

TABLE 49 SELECTED U.S. KIDNEY AND URINARY SYSTEM DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY.....	123
RESEARCH AND DEVELOPMENT	123
TABLE 50 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE	124
MARKET SIZE AND GROWTH.....	124
Total Market	124
TABLE 51 TOTAL U.S. KIDNEY AND URINARY SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	125
FIGURE 22 TOTAL U.S. KIDNEY AND URINARY SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS).....	125
TABLE 52 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS).....	126
FIGURE 23 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS).....	127
Market Percent Distribution by Product Sub-type	127
TABLE 53 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%).....	128
FIGURE 24 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%).....	128
COMPETITIVE STRUCTURE AND MARKET SHARE.....	128
TABLE 54 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	129
FIGURE 25 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%).....	130
MALIGNANT AND IMMUNE DISEASE DRUGS	130
OVERVIEW	130
PRODUCT DESCRIPTION	131
Product Description (Continued)	132
Product Description (Continued)	133
Product Description (Continued)	134
Product Description (Continued)	135
TABLE 55 SELECTED U.S. MALIGNANT AND IMMUNE DISEASE DRUGS, DRUGS COMMONLY USED BY THE ELDERLY.....	136
RESEARCH AND DEVELOPMENT	137
TABLE 56 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE	137
MARKET SIZE AND GROWTH.....	138
Total Market	138
TABLE 57 TOTAL U.S. MALIGNANT AND IMMUNE DISEASE DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	138
FIGURE 26 TOTAL U.S. MALIGNANT AND IMMUNE DISEASE DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS, %).....	139
TABLE 58 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS).....	139

<i>FIGURE 27 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS</i>	
<i>MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS)</i>	140
COMPETITIVE STRUCTURE AND MARKET SHARE.....	140
<i>TABLE 59 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS MARKET,</i>	
<i>COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS)</i>	141
<i>FIGURE 28 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS</i>	
<i>MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS)</i>	141
METABOLIC, ENDOCRINE AND HORMONE DRUGS	142
OVERVIEW	142
Osteoporosis	142
Diabetes	143
Thyroid Disorders.....	144
PRODUCT DESCRIPTION	144
Product Description (Continued)	145
<i>TABLE 60 SELECTED U.S. METABOLIC, ENDOCRINE, AND HORMONE DRUG</i>	
<i>COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY</i>	146
RESEARCH AND DEVELOPMENT	147
<i>TABLE 61 U.S. ELDERLY METABOLIC, ENDOCRINE, AND HORMONE DRUGS</i>	
<i>UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE</i>	147
MARKET SIZE AND GROWTH.....	148
Total Market	148
<i>TABLE 62 TOTAL U.S. METABOLIC, ENDOCRINE, AND HORMONE DRUG</i>	
<i>MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE</i>	
<i>65, THROUGH 2007 (\$ BILLIONS)</i>	148
<i>FIGURE 29 TOTAL U.S. METABOLIC, ENDOCRINE, AND HORMONE DRUG</i>	
<i>MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE</i>	
<i>65, 2002 AND 2007 (\$ BILLIONS, %)</i>	149
<i>TABLE 63 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS</i>	
<i>MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS)</i>	150
<i>FIGURE 30 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS</i>	
<i>MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS)</i>	150
Market Percent Distribution by Product Sub-type	151
<i>TABLE 64 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS</i>	
<i>MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)</i>	151
<i>FIGURE 31 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS</i>	
<i>MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007</i>	152
COMPETITIVE STRUCTURE AND MARKET SHARE.....	152
<i>TABLE 65 U.S. ELDERLY METABOLIC, ENDOCRINE, AND HORMONE DRUGS</i>	
<i>MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS)</i>	153
<i>FIGURE 32 U.S. ELDERLY METABOLIC, ENDOCRINE, AND HORMONE DRUGS</i>	
<i>MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)</i>	154
RESPIRATORY DRUGS	154
OVERVIEW	154
PRODUCT DESCRIPTION	154
Product Description (Continued)	155
<i>TABLE 66 SELECTED U.S. RESPIRATORY DRUG COMPARISON, DRUGS</i>	
<i>COMMONLY USED BY THE ELDERLY</i>	156
RESEARCH AND DEVELOPMENT	157
<i>TABLE 67 U.S. ELDERLY RESPIRATORY DRUGS UNDER DEVELOPMENT, BY</i>	
<i>DEVELOPER AND DEVELOPMENT PHASE</i>	157

MARKET SIZE AND GROWTH.....	158
Total Market	158
TABLE 68 TOTAL U.S. RESPIRATORY DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS)	158
FIGURE 33 TOTAL U.S. RESPIRATORY DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS, %).....	158
Total Market (Continued).....	159
TABLE 69 U.S. ELDERLY RESPIRATORY DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS).....	160
FIGURE 34 U.S. ELDERLY RESPIRATORY DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS).....	160
Market Percent Distribution by Product Sub-type	161
TABLE 70 U.S. ELDERLY RESPIRATORY DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%).....	161
FIGURE 35 U.S. ELDERLY RESPIRATORY DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%).....	162
COMPETITIVE STRUCTURE AND MARKET SHARE.....	162
TABLE 71 U.S. ELDERLY RESPIRATORY DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	163
FIGURE 36 U.S. ELDERLY RESPIRATORY DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	164
SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS	164
OVERVIEW	164
PRODUCT DESCRIPTION	165
TABLE 72 SELECTED U.S. SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY.....	166
RESEARCH AND DEVELOPMENT	166
TABLE 73 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE	167
MARKET SIZE AND GROWTH.....	167
Total Market	167
TABLE 74 TOTAL U.S. SEXUAL DYSFUNCTION AND GENITAL ORGAN MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 (\$ BILLIONS).....	168
FIGURE 37 TOTAL U.S. SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 (\$ BILLIONS, %).....	168
TABLE 75 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 (\$ MILLIONS)	169
FIGURE 38 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 (\$ MILLIONS).....	170
Market Percent Distribution by Product Sub-type	170
TABLE 76 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)	171
FIGURE 39 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2002 AND 2007 (%).....	171
COMPETITIVE STRUCTURE AND MARKET SHARE.....	171
TABLE 77 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (\$ MILLIONS).....	172

<i>FIGURE 40 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)</i>	173
MARKET SUMMARY	174
TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY	174
<i>TABLE 78 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY BY SEGMENT, THROUGH 2007 (\$ MILLIONS)</i>	174
<i>FIGURE 41 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY BY SEGMENT, 2002 AND 2007</i>	175
<i>TABLE 79 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, THROUGH 2007 (\$ BILLIONS)</i>	175
<i>FIGURE 42 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, 2002 AND 2007 (%)</i>	176
TECHNOLOGY.....	176
CURRENT USES OF TECHNOLOGY	176
DRUG PATENT EVALUATION	177
Drug Patent Evaluation (Continued)	178
<i>TABLE 80 U.S. PATENT AND EXCLUSIVITY INFORMATION BY DRUG* FOR COMMONLY USED DRUGS IN THE ELDERLY</i>	179
<i>TABLE 80 (CONTINUED)</i>	180
<i>TABLE 80 (CONTINUED)</i>	181
<i>TABLE 80 (CONTINUED)</i>	182
<i>TABLE 80 (CONTINUED)</i>	183
<i>TABLE 80 (CONTINUED)</i>	184
<i>TABLE 80 (CONTINUED)</i>	185
<i>TABLE 80 (CONTINUED)</i>	186
<i>TABLE 80 (CONTINUED)</i>	187
<i>TABLE 80 (CONTINUED)</i>	188
<i>TABLE 80 (CONTINUED)</i>	189
<i>TABLE 80 (CONTINUED)</i>	190
<i>TABLE 80 (CONTINUED)</i>	191
<i>TABLE 80 (CONTINUED)</i>	192
<i>TABLE 80 (CONTINUED)</i>	193
TECHNOLOGY PATENT EVALUATION.....	193
<i>TABLE 81 EXAMPLES OF TECHNOLOGY PATENTS BENEFITING THE U.S. ELDERLY POPULATION, BY NUMBER AND COMPANY</i>	194
INDUSTRY PARTICIPANTS AND COMPETITIVE ANALYSIS.....	195
<i>TABLE 82 INDUSTRY PARTICIPANTS BY PRODUCT TYPE</i>	195
<i>TABLE 82 (CONTINUED)</i>	196
<i>TABLE 82 (CONTINUED)</i>	197
<i>FIGURE 43 INDUSTRY PARTICIPATION BY NUMBER OF SEGMENTS WITH PRODUCT PARTICIPATION</i>	198
<i>FIGURE 44 DISTRIBUTION OF INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT PARTICIPATION (%)</i>	198
<i>FIGURE 44 (CONTINUED)</i>	199
<i>TABLE 83 APPROVED DRUGS USED FOR THE ELDERLY BY MANUFACTURER</i>	199
<i>TABLE 83 (CONTINUED)</i>	200
<i>TABLE 83 (CONTINUED)</i>	201
<i>TABLE 83 (CONTINUED)</i>	202
COMPANY PROFILES	202

ABBOTT LABORATORIES, INC.....	202
ALCON LABORATORIES, INC.....	203
ALLERGAN, INC.....	203
ALZA CORP.....	204
AMGEN, INC.....	204
ASTRAZENECA PLC.....	205
AVENTIS PHARMACEUTICALS, INC.....	205
BAUSCH & LOMB, INC.....	206
BAYER CORP.....	206
BOEHRINGER INGELHEIM GMBH (ROXANE LABORATORIES, INC.).....	207
ROXANE LABORATORIES, INC.....	207
BRISTOL-MYERS SQUIBB COMPANY (APOTHECON, INC., BRISTOL-MYERS SQUIBB ONCOLOGY, WESTWOOD SQUIBB).....	208
Apothecon, Inc.....	208
Bristol-Myers Squibb Oncology.....	208
Westwood Squibb.....	208
ELI LILLY & COMPANY.....	209
FOREST LABORATORIES, INC.....	209
GLAXOSMITHKLINE PLC.....	210
JOHNSON & JOHNSON (JANSSEN PHARMACEUTICA, ORTHO-MCNEIL PHARMACEUTICALS, ORTHO BIOTECH PRODUCTS).....	210
Janssen Pharmaceutica Products, L.P.....	210
Ortho-McNeil Pharmaceuticals, Inc.....	211
Ortho Biotech Products, L.P.....	211
MERCK & CO., INC.....	211
NOVARTIS PHARMACEUTICALS CORP. (NOVARTIS OPHTHALMICS, INC.).....	212
Novartis Ophthalmics, Inc.....	212
PAR PHARMACEUTICAL, INC.....	213
PFIZER, INC.....	213
Agouron Pharmaceuticals, Inc.....	213
PHARMACIA CORPORATION.....	214
ROCHE GROUP (HOFFMANN-LAROCHE, INC.).....	214
Hoffmann-LaRoche, Inc.....	215
SCHERING-PLOUGH CORPORATION.....	215
TAP PHARMACEUTICAL PRODUCTS, INC.....	216
WYETH.....	216

APPENDICES.....	217
FIGURE 45 COMPANIES MENTIONED IN THE MARKET FOR DRUGS FOR THE ELDERLY.....	217
FIGURE 45 (CONTINUED).....	218

APPENDIX I: CONTACT INFORMATION FOR LEADING DRUG	
MANUFACTURERS	218
ABBOTT LABORATORIES	218
AKORN, INC.	218
ALCON LABORATORIES, INC.	218
ALLERGAN, INC.	218
ALZA CORP.	219
AMARIN PHARMACEUTICALS, INC.	219
AMGEN, INC.	219
APOTHECON, INC.	219
ASTRAZENECA PLC.	219
ASTRAZENECA PHARMACEUTICALS LP	219
ATHENA DIAGNOSTICS	220
AVENTIS PHARMACEUTICALS, INC.	220
BASF CORP.	220
BAUSCH & LOMB, INC.	220
BARR LABORATORIES, INC.	220
BAXTER HEALTHCARE CORP.	220
BAYER CORP.	221
BEDFORD LABORATORIES.	221
BIOVAIL PHARMACEUTICALS, INC. (PREVIOUSLY DJ PHARMA).....	221
BRISTOL-MYERS SQUIBB ONCOLOGY	221
BRISTOL-MYERS SQUIBB CO.	221
CELLTECH GROUP PLC	221
DURAMED	221
ELAN PHARMACEUTICALS, INC.	222
ELI LILLY & CO.	222
ENDO PHARMACEUTICALS, INC.	222
FIRST HORIZON PHARMACEUTICAL CORP.	222
FLEMING & CO.	222
FOREST LABORATORIES, INC.	222
FUJISAWA PHARMACEUTICAL CO., LTD.	223
GENETECH, INC.	223
GILEAD SCIENCES, INC.	223
GLAXOSMITHKLINE PLC	223
HOFFMANN-LA ROCHE, INC.	223
ICN PHARMACEUTICALS, INC.	223
IMMUNEX CORP.	224
JANSSEN PHARMACEUTICA PRODUCTS, L.P	224
JOHNSON & JOHNSON.	224
JOHNSON & JOHNSON.	224
Tel: 732-524-0400	224
JONES PHARMA, INC.	224

KING PHARMACEUTICALS, INC.....	224
KNOLL LABORATORIES	224
ABBOTT LABORATORIES	224
LIPOSOME CO., THE	225
ELAN CORP., PLC.....	225
MERCK & CO., INC.....	225
MONARCH PHARMACEUTICALS.....	225
MYLAN LABORATORIES, INC.	225
NOVARTIS PHARMACEUTICALS CORP.....	225
NOVARTIS OPHTHALMICS, INC.	226
NOVARTIS PHARMACEUTICALS CORP.....	226
NOVO NORDISK A/S	226
NOVO ALLÉ.....	226
NOVO NORDISK PHARMACEUTICALS, INC.....	226
OCLASSEN PHARMACEUTICALS, INC.	226
WATSON PHARMACEUTICALS, INC.	226
ORTHO-MCNEIL PHARMACEUTICAL, INC.....	226
JOHNSON & JOHNSON.....	226
ORTHO BIOTECH PRODUCTS, L.P.	227
JOHNSON & JOHNSON.....	227
PAR PHARMACEUTICAL, INC.	227
PHARMACEUTICAL RESOURCES, INC.....	227
PFIZER, INC.	227
PHARMACIA CORP.	227
PURDUE PHARMA L.P.	227
PROCTER & GAMBLE CO., THE	227
ROXANE LABORATORIES, INC.	228
SALIX PHARMACEUTICALS, LTD.....	228
SANKYO PHARMA, INC.	228
SANOFI-SYNTHELABO	228
SAVAGE LABORATORIES.....	228
SCHERING-PLOUGH CORP.....	228
SCHWARZ PHARMA, INC.....	229
SIGMA-TAU, INC.	229
SOLVAY PHARMACEUTICALS, INC.	229
SOMERSET PHARMACEUTICALS, INC.....	229
TAP PHARMACEUTICAL PRODUCTS, INC.....	229
UCB PHARMA	229
UNIMED PHARMACEUTICALS, INC.....	230
SOLVAY PHARMACEUTICALS, INC.	230
UPSHER-SMITH LABORATORIES.....	230
WALLACE PHARMACEUTICALS.....	230
WARNER-CHILCOTT, PLC.....	230
WARNER-LAMBERT	230

PFIZER, INC.	230
WELLSPRING PHARMACEUTICAL CORP.	230
WESTWOOD-SQUIBB	231
BRISTOL-MYERS SQUIBB CO.	231
WOMEN FIRST HEALTHCARE, INC.	231
WYETH.....	231
APPENDIX II: OTHER MANUFACTURERS AND COMPANIES	231
3M PHARMACEUTICALS	231
3M CO.	231
AAIPHARMA, INC.....	231
ABBOTT HOSPITAL PRODUCTS.....	232
ABBOTT LABORATORIES	232
ACTELION PHARMACEUTICALS U.S., INC.....	232
ADOLOR CORP.	232
AEROPHARM TECHNOLOGY, INC.....	232
AFFERON CORP.	232
ALEXION PHARMACEUTICALS, INC.	232
ALLOS THERAPEUTICS, INC.....	233
AMYLIN PHARMACEUTICALS, INC.	233
ANTEX BIOLOGICS.....	233
ANTIGENICS, INC.....	233
APOTEX CORP.	233
ARADIGM CORP.	233
ARTECEL SCIENCES, INC.....	233
ATRIX LABORATORIES.....	234
AUXILIUM PHARMACEUTICALS, INC.	234
AVENTIS PHARMA	234
AVENTIS.....	234
AVI BIOPHARMA.....	234
AXCAN PHARMA, INC.	234
AXONYX, INC.....	235
BARR LABORATORIES, INC.....	235
BAYER AG	235
BERLEX LABORATORIES, INC.	235
BIONUMERIK PHARMACEUTICALS, INC.	235
BOEHRINGER INGELHEIM GMBH.....	235
BONE CARE INTERNATIONAL, INC.....	236
BOSTON LIFE SCIENCES, INC.	236
CENTOCOR, INC.....	236
CEPHALON, INC.....	236
COLLATERAL THERAPEUTICS, INC.....	236
CORIXA CORP.....	236
CORTEX PHARMACEUTICALS, INC.	237
CUBIST PHARMACEUTICALS, INC.	237

CURACYTE AG.....	237
CV THERAPEUTICS, INC.	237
DEPOMED, INC.	237
DIACRIN, INC.	237
DIMETHAID RESEARCH, INC.....	238
DISCOVERY LABORATORIES, INC.	238
DR. REDDY'S LABORATORIES, INC.....	238
E.I. DUPONT DE NEMOURS & CO.....	238
EISAI CO., LTD.	238
ENDOVASC LTD., INC.	238
FARO PHARMACEUTICALS	239
FIRST HORIZON PHARMACEUTICAL CORP.....	239
G & W LABORATORIES, INC.	239
GENESIS RESEARCH & DEVELOPMENT CORP., LTD.	239
GENEVA PHARMACEUTICALS, INC.....	239
GENOME THERAPEUTICS CORP.....	239
GENZYME CORP.	240
GUILFORD PHARMACEUTICALS, INC.....	240
HERMES BIOSCIENCES, INC.	240
HUMAN GENOME SCIENCES, INC.....	240
ICOS CORP.	240
IDEC PHARMACEUTICALS CORP.....	240
IMPAX LABORATORIES, INC.	241
INHALE THERAPEUTIC SYSTEM, INC.	241
INKINE PHARMACEUTICAL CO., INC.	241
IMCLONE SYSTEMS, INC.	241
INSITE VISION, INC.	241
INSMED, INC.	241
INDEVUS PHARMACEUTICALS, INC.	242
ISIS PHARMACEUTICALS, INC.	242
IVAX CORP.	242
KYORIN PHARMACEUTICAL CO., LTD.....	242
LG CHEM, LTD.	242
LIGAND PHARMACEUTICALS, INC.....	242
LION BIOSCIENCE, INC.	243
MACROCHEM CORP.	243
MCNEIL CONSUMER HEALTHCARE	243
MEDAREX, INC.....	243
MEDICINES CO., THE	243
MEDIGENE AG	243
METABOLEX, INC.....	244
MILKHAUS LABORATORY, INC.	244
MIRAVANT MEDICAL TECHNOLOGIES	244
MONSANTO CO.	244

MYOGEN, INC.....	244
NASTECH PHARMACEUTICAL CO., INC.	244
NEUROBIOLOGICAL TECHNOLOGIES, INC.....	245
NEUROCRINE BIOSCIENCES, INC.....	245
NEUROGEN CORP.	245
NEXMED, INC.....	245
NITROMED, INC.....	245
NORTHWEST BIOTHERAPEUTICS.....	245
NOVEN PHARMACEUTICALS, INC.....	246
NPS PHARMACEUTICALS, INC.....	246
ORGANON, INC.	246
ORION PHARMA.....	246
PALATIN TECHNOLOGIES, INC.....	246
PHARMACEUTICAL RESOURCES, INC.....	246
PHARMACYCLICS, INC.....	247
POLYMEDICA CORP.	247
PRAECIS PHARMACEUTICALS, INC.	247
PROFILE THERAPEUTICS PLC.....	247
PROMETHEUS LABORATORIES, INC.	247
PROTEIN DESIGN LABS, INC.	247
QLT, INC.....	248
ROCHE GROUP.....	248
SCHERING AG.....	248
SCIOS, INC.	248
SEPRACOR, INC.	248
SERONO LABORATORIES, INC.	248
SHEFFIELD PHARMACEUTICALS, INC.....	249
SHIRE PHARMACEUTICALS GROUP PLC.....	249
SPECTRUM PHARMACEUTICAL.....	249
SUPERGEN CORP.	249
SYN X PHARMA, INC.....	249
SYNSORB BIOTECH, INC.....	249
TAKEDA CHEMICAL INDUSTRIES, LTD.	250
TEVA PHARMACEUTICALS USA.....	250
TITAN PHARMACEUTICALS, INC.....	250
UNITED THERAPEUTICS CORP.....	250
VASOGEN, INC.	250
VICAL, INC.	250
VIROPHARMA, INC.....	251
VIVUS, INC.....	251
WATSON PHARMACEUTICALS, INC.....	251
ZONAGEN, INC.....	251
APPENDIX III: ASSOCIATION, ORGANIZATIONS, AND UNIVERSITIES.....	251

AMERICAN ASSOCIATION OF RETIRED PERSONS	251
BAYLOR UNIVERSITY.....	251
CENTER ON AN AGING SOCIETY.....	252
FEDERAL TRADE COMMISSION (FTC)	252
FOOD AND DRUG ADMINISTRATION (FDA).....	252
GERONTOLOGY RESEARCH CENTER.....	252
INSTITUTE FOR DIABETES DISCOVERY, THE	252
NATIONAL COUNCIL ON THE AGING, THE (NCOA).....	252
NATIONAL INSTITUTE ON AGING (NIA)	253
NATIONAL INSTITUTES OF HEALTH.....	253
UNIVERSITY OF OKLAHOMA.....	253
UNIVERSITY OF SOUTH FLORIDA.....	253
UNIVERSITY OF TEXAS AT AUSTIN	253
UNIVERSITY OF TORONTO	253
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES, THE....	254
U.S. PATENT AND TRADEMARK OFFICE.....	254